Table 2. Tariffs of examinations and treatments—Toxoscreen project.
| Code/Source | Tariffs (euros) |
|
|---|---|---|
| Pregnancy monitoring | ||
| Ultrasound examination (1st trimester) | JNQM001/CCAMa | 36.35 |
| Ultrasound fetal morphology and biometry (2nd trimester) | JQQM018/CCAMa | 100.20 |
| Ultrasound fetal morphology and biometry (3rd trimester) | JQQM016/CCAMa | 100.20 |
| Screening | ||
| Standard toxoplasmosis serology (IgG+IgM by 2 techniques) |
B40/NABMb | 10.80 |
| Serologic confirmation (2 isotypes including IgG by two techniques on two samples) |
B60/NABMb | 16.20 |
| Toxoplasmosis confirmation | ||
| Amniocentesis | JPHJ002/CCAMa | 68.58 |
| Mouse inoculation | B300/NABMb | 81.00 |
| PCR | B600/NABMb | 162.00 |
| Termination | JND001/CCAMa | 82.39 |
| Neonatal examinations | ||
| Consultation of pediatrician | CSM/NGAPc | 46.00 |
| Skull radiographd | LAQK003/CCAMa | 23.94 |
| Transfontanellar ultrasound examination | AAQM002/CCAMa | 37.80 |
| Eye examination in newborns (until 28th days after birth) | BGQP004/CCAMa | 36.92 |
| Computerized tomography of the head | ACQK001/CCAMa | 25.27 |
| Treatments and related follow-up | ||
| Spiramycine (16 tb 3 MUI) | French Public Database of Drugs | 11.10 |
| Adiazine/ Sulfadiazine (20 tb 500 mg) | 3.62 | |
| Malocide/ Pyriméthamine (20 tb 50 mg) | 13.55 | |
| Lederfoline/folinic acid (30 tb 25 mg)–pregnancy | 30.05 | |
| Fansidar®/ Sulfadoxine +Pyrimethamine (3 tbt) | 1.98 | |
| Folinoral® /acid folinic) (14 capsule-shape tbt 25 mg)–children | 14.46 | |
| Blood count | B26 (1104)/NABMb | 7.02 |
| Proteinuria | B4 (2004)/NABMb | 0.52 |
| Ophthalmological follow-up | CS/NGAPc | 30.00 |
a: Classification Commune des Actes Médicaux;
b: Nomenclature des Actes de Biologie Médicale;
c: Nomenclature Générale des Actes Professionnels;
d: This procedure is no longer used but were part of costs in the history of the screening program.